For ERα negative (ERα−), progesterone receptor negative (PR−), and HER2+ (ERα−/PR−/HER2+) breast tumors, a combination of pertuzumab, trastuzumab, and docetaxel has been effective (59). This evidence concerns the gene ERBB2 and breast neoplasm.